Derlis E. Gonzalez
Asuncion, ASU, Paraguay
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease.
Journal: Genetics in medicine : official journal of the American College of Medical Genetics
Published: March 20, 2023
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
Journal: Leukemia & lymphoma
Published: July 06, 2019
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.
Journal: Journal of inherited metabolic disease
Published: July 23, 2018
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
Journal: Cancer chemotherapy and pharmacology
Published: September 28, 2017
Latin America: the next region for haematopoietic transplant progress.
Journal: Bone marrow transplantation
Published: May 04, 2017
Response to request by journal editorship from Blood Cells, Molecules and Diseases in reference to a "Dear Editor" letter to the Pastores et al. paper, 2016.
Journal: Blood cells, molecules & diseases
Published: April 10, 2017
Latin America: the next region for haematopoietic transplant progress.
Journal: Bone marrow transplantation
Published: August 13, 2016
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
Journal: American journal of hematology
Published: December 12, 2014
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Journal: American journal of hematology
Published: October 30, 2012
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
Journal: American journal of hematology
Published: October 30, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026